Mirati Therapeutics Inc. is a company in the U.S. stock market and it is a holding in 42 U.S.-traded ETFs. MRTX has around 2.5M shares in the U.S. ETF market. The largest ETF holder of MRTX is the SPDR S&P Biotech ETF (XBI), with approximately 601.61K shares. Investors may also find of interest that the ETF with the largest allocation to MRTX stock is ALPS Medical Breakthroughs ETF (SBIO), with a portfolio weight of 3.54%. On average, U.S. ETFs allocate 0.41% of MRTX to their portfolios.

Additionally, MRTX is a favorite stock for Vanilla and Multi-factor ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with MRTX as a holding is the Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a return of 27.53%.